Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme

BACKGROUND: Patients with advanced melanoma are faced with a poor prognosis and, until recently, limited treatment options. Ipilimumab, a novel immunotherapy that blocks cytotoxic T-lymphocyte-associated antigen-4, was the first agent to improve survival of patients with advanced melanoma in a rando...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Altomonte, Maresa, Di Giacomo, Anna Maria, Queirolo, Paola, Ascierto, Paolo Antonio, Spagnolo, Francesco, Bajetta, Emilio, Calabrò, Luana, Danielli, Riccardo, de Rosa, Francesco, Maur, Michela, Chiarion-Sileni, Vanna, Ferrucci, Pier Francesco, Giannarelli, Diana, Testori, Alessandro, Ridolfi, Ruggero, Maio, Michele
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4029467/
https://ncbi.nlm.nih.gov/pubmed/24423086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-32-82
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak